Literature DB >> 19752290

The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide.

Norman M Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19752290     DOI： 10.1161/HYPERTENSIONAHA.109.135061

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  10 in total

1.  Reduced Nhe1 (Na+-H+ Exchanger-1) Function Protects ApoE-Deficient Mice From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysms.

Authors:  Cong-Lin Liu; Xin Liu; Yunzhe Wang; Zhiyong Deng; Tianxiao Liu; Galina K Sukhova; Gregory R Wojtkiewicz; Rui Tang; Jin-Ying Zhang; Samuel Achilefu; Matthias Nahrendorf; Peter Libby; Xiaofang Wang; Guo-Ping Shi
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

2.  Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate.

Authors:  Mark A Peterzan; Rebecca Hardy; Nish Chaturvedi; Alun D Hughes
Journal:  Hypertension       Date:  2012-04-30       Impact factor: 10.190

Review 3.  Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?

Authors:  F Wilford Germino
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

4.  Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors.

Authors:  Yoshiyuki Okada; Sara S Jarvis; Stuart A Best; Tiffany B Bivens; Beverley Adams-Huet; Benjamin D Levine; Qi Fu
Journal:  J Physiol       Date:  2013-09-23       Impact factor: 5.182

5.  Renewed interest in chlorthalidone: evidence from the Veterans Health Administration.

Authors:  Michael E Ernst; Brian C Lund
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08-30       Impact factor: 3.738

6.  Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.

Authors:  F J Martinez-Martin; H Rodriguez-Rosas; I Peiro-Martinez; P Soriano-Perera; P Pedrianes-Martin; C Comi-Diaz
Journal:  J Hum Hypertens       Date:  2010-11-25       Impact factor: 3.012

Review 7.  Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

Authors:  Theodore W Kurtz; Takashi Kajiya
Journal:  Vasc Health Risk Manag       Date:  2012-02-28

8.  Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.

Authors:  Lakshmi Manasa S Chekka; Arlene B Chapman; John G Gums; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Am J Med       Date:  2021-01-09       Impact factor: 5.928

9.  Resistant hypertension: an approach to management in primary care.

Authors:  Julian P Yaxley; Sam V Thambar
Journal:  J Family Med Prim Care       Date:  2015 Apr-Jun

Review 10.  Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction.

Authors:  Katherine Lang; Erik H Van Iterson; Luke J Laffin
Journal:  Cardiol Ther       Date:  2020-11-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.